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Abstract Glucagon-like peptide-1 (GLP-1) is an insulin-
releasing hormone clinically exploited for glycaemic con-
trol in diabetes, which also confers acute cardioprotection
and benefits in experimental/clinical heart failure. We
specifically investigated the role of the GLP-1 mimetic,
exendin-4, in post-myocardial infarction (MI) remodelling,
which is a key contributor to heart failure. Adult female
normoglycaemic mice underwent coronary artery ligation/
sham surgery prior to infusion with exendin-4/vehicle for
4 weeks. Metabolic parameters and infarct sizes were
comparable between groups. Exendin-4 protected against
cardiac dysfunction and chamber dilatation post-MI and
improved survival. Furthermore, exendin-4 modestly de-
creased cardiomyocyte hypertrophy/apoptosis but
markedly attenuated interstitial fibrosis and myocardial
inflammation post-MI. This was associated with altered
extracellular matrix (procollagen IaI/IIIaI, connective tis-
sue growth factor, fibronectin, TGF-b3) and inflammatory
(IL-10, IL-1b, IL-6) gene expression in exendin-4-treated
mice, together with modulation of both Akt/GSK-3b and
Smad2/3 signalling. Exendin-4 also altered macrophage
response gene expression in the absence of direct actions
on cardiac fibroblast differentiation, suggesting cardiopro-
tective effects occurring secondary to modulation of in-
flammation. Our findings indicate that exendin-4 protects
against post-MI remodelling via preferential actions on
inflammation and the extracellular matrix independently of
its established actions on glycaemic control, thereby sug-
gesting that selective targeting of GLP-1 signalling may be
required to realise its clear therapeutic potential for post-
MI heart failure.
Keywords Glucagon-like peptide-1  Myocardial
infarction  Cardiac remodelling  Extracellular matrix 
Inflammation
Introduction
Chronic heart failure (CHF) affects up to 2 % of the adult
population in the western world and carries a poor prog-
nosis, with the underlying aetiology shifting towards is-
chaemia [1, 2]. Acute remodelling in the infarct zone
occurs within the first few days after myocardial infarction
(MI) and involves apoptosis and inflammation which drive
scar formation, whereas post-MI remodelling affecting the
remote viable myocardium includes initial adaptive chan-
ges in cardiomyocyte biology and the extracellular matrix
(ECM) progressing to maladaptive left ventricular (LV)
dilatation, chronic myocardial inflammation, cardiomyo-
cyte hypertrophy/apoptosis and interstitial fibrosis, which
contribute to associated contractile dysfunction and ulti-
mately CHF [3]. Despite optimal pharmacological and
surgical management of post-MI patients there remains a
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substantial incidence of CHF [4, 5], so the need for more
effective therapeutic strategies is clear.
In this regard, the incretin hormone, glucagon-like pep-
tide-1 (GLP-1), is emerging as a potential candidate. Beyond
its established role in glycaemic control, accumulating evi-
dence supports other important physiological roles for GLP-
1, particularly in the cardiovascular system [6, 7], where the
GLP-1 receptor (GLP-1R) is widely expressed and mediates
key functions including heart rate/contractility, cardiac
structure/contractility, blood pressure and vascular tone [8–
12]. Importantly, GLP-1 also confers beneficial actions on
cardiovascular disease, both experimental and clinically, in
the presence or absence of diabetes [13–18].
The majority of studies investigating cardiac effects of
GLP-1 have focused on its actions in ischaemia and ability
to protect cardiomyocytes from acute damage. For exam-
ple, it is well established that GLP-1R agonists and
dipeptidyl peptidase-4 (DPP-4) inhibitors, which increase
endogenous GLP-1, reduce infarct size after experimental
ischaemia and enhance functional recovery upon reperfu-
sion [8, 19, 20]. Furthermore, the GLP-1R agonist, li-
raglutide, increases survival in experimental MI, and
cardiac function after ischaemia–reperfusion injury is im-
proved in DPP-4-/- mice [15, 17]. GLP-1 also protects
against LV dysfunction in experimental models of dilated
cardiomyopathy, hypertensive CHF and MI, at least partly
by increasing myocardial glucose uptake [14, 16, 21].
Importantly these benefits appear to translate to the clinical
setting with GLP-1 improving cardiac function in CHF and
in MI patients after primary angioplasty [18, 22].
Although the acute cardioprotective actions of GLP-1 are
well established, little attention has previously been paid to
specific effects on post-MI remodelling, which is a major
contributor to CHF progression [3]. However, two studies
have now reported beneficial actions of the GLP-1 ana-
logues, AC3174 and exendin-4, on post-MI survival and
cardiac structure/function in rodent models, when adminis-
tered from 2 days and 2 weeks after coronary artery ligation,
respectively [21, 23], although another study failed to de-
monstrate equivalent beneficial effects when liraglutide was
given 7 days post-MI [24]. As previous work suggests that
GLP-1 modulates several signalling pathways related to
specific facets of post-MI remodelling, including car-
diomyocyte apoptosis, fibrosis and inflammation [25–30],
which are key determinants of CHF progression, a more
detailed focus on individual remodelling components was
considered to be crucial. The aim of this study was therefore
to precisely define the apparently favourable actions of the
peptide in this setting, testing the hypothesis that exendin-4
attenuates post-MI remodelling via differential modulation
of distinct aspects of the remodelling phenotype. Impor-
tantly, we report for the first time specific beneficial actions
of exendin-4 on post-MI remodelling, which appear to
involve preferential targeting of the ECM secondary to
modulation of myocardial inflammation.
Methods
Experimental model
Female C57BL/6J mice (8–12 weeks; Harlan UK) were
used throughout this study and were housed under constant
climatic conditions with free access to food and water. All
experimental procedures were performed in accordance with
the Guidance on the Operation of the Animals (Scientific
Procedures) Act, 1986 (UK) and approved by the Queen’s
University Belfast Animal Welfare and Ethical Review
Body. Experimental animals were randomised (by drawing
of lots) and subjected to permanent ligation of the left an-
terior descending coronary artery under 2 % isoflurane/
oxygen anaesthesia, or sham surgery which involved an
identical procedure with the exception of coronary artery
ligation, and subsequent analyses performed at 4 weeks.
Buprenorphine analgesia (0.05 mg/kg i.m.) was adminis-
tered prior to and after surgery, as required. Female mice
were used as previous studies have shown them to carry
significantly lower peri-operative mortality versus males
[31]. To investigate the effects of GLP-1 on post-MI re-
modelling, MI or sham-operated mice were randomly as-
signed to be chronically infused with either the DPP-4
resistant GLP-1 mimetic, exendin-4 (at a concentration
employed in previous studies relating to the anti-diabetic
and cardioprotective actions of GLP-1; 25 nmol/kg/day; GL
Biochem, average purity 90 %) [12, 15, 16, 32], or saline
control via an osmotic minipump (Alzet model 1004) im-
planted immediately after MI surgery. For ex vivo analysis
of infarct size and gene/protein expression, animals were
killed by sodium pentobarbitone overdose before hearts
were excised and either perfused with Evan’s blue dye or
non-infarcted tissue frozen in liquid nitrogen and stored at
-80 C for further studies. For analysis of post-MI remod-
elling, hearts were arrested in diastole by injection of 10 %
KCl, fixed in 10 % neutral-buffered formalin solution,
paraffin-embedded and sectioned. A minimum of five ani-
mals per group were studied for all protocols.
Assessment of plasma glucose, insulin and lipids
Terminal blood samples were collected by cardiac puncture
into heparinised tubes and centrifuged at 10,000g for
10 min to obtain plasma fractions. Plasma samples were
analysed using enzymatic assay kits (Analox Ltd) for
glucose (GMRD-002A using glucose oxidase), cholesterol
(GMRD-084 using cholesterol esterase) and triglyceride
(GMRD-195 using lipase) detected on a GM7 Micro-Stat
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Analyser (Analox Instruments Ltd). Plasma insulin con-
centrations were assayed using an ELISA kit (ALPCO
Diagnostics), measuring absorbance at 450 nm on a mi-
croplate reader (Tecan Safire). Plasma glycated hae-
moglobin, HbA1c, was assessed using a commercially
available assay kit (Helena Laboratories), measuring ab-
sorbance at 415 nm on a microplate reader (Tecan Safire)
and expressed as percentage of total haemoglobin.
Plasma adipokine expression
Adipokine protein expression was assessed in six pooled
plasma samples from each experimental group using a
Proteome ProfilerTM antibody array (R&D Systems).
Infarct size
Excised hearts were initially perfused retrogradely with
Evans blue dye (1 % in saline) to determine area at risk.
Hearts were then sliced into five serial transverse sections
(1 mm) and incubated in 1 % triphenyltetrazolium chloride
at 37 C to identify infarcted myocardium. Infarct area,
area at risk and total LV area from each section were
measured using computerised planimetry (ImageJ), and
totalled for all sections. Infarct size was expressed as a
percentage of area at risk.
Echocardiography and invasive assessment of cardiac
function
Mice were anaesthetised with 1.5 % isoflurane/oxygen,
placed on a warming pad, and imaged in the supine posi-
tion using a Vevo770 ultrasound system with high-fre-
quency 45 MHz RMV707B scanhead (VisualSonics, Inc.).
M-mode parasternal short-axis scans at papillary muscle
level were used to quantify LV end-diastolic (LVEDD) and
end-systolic diameters (LVESD) from which % fractional
shortening was calculated (LVEDD - LVESD)/
LVEDD 9 100. Parasternal long-axis scans were used to
provide additional data on LV end-diastolic (LVEDV) and
end-systolic volumes (LVESV) and ejection fraction and
pulse-wave Doppler was used to assess mitral valve flow
(E/A ratio) as a measure of diastolic function. Isoflurane
was then increased to 2 % before the right carotid artery
was cannulated with a high-fidelity 1.2F pressure catheter
(FTS-1211B-0018; Scisense Inc.), aortic pressure mea-
sured, and the catheter advanced into the LV for recording
of steady-state function.
Assessment of post-MI remodelling
Following killing, hearts were weighed and measurements
normalised to total body weight. All histological analyses
were performed on fixed (10 % neutral-buffered formalin),
paraffin-embedded LV sections (5 lm). Cardiomyocyte
cross-sectional area was determined by H&E staining,
analysing cells with centrally located nuclei. Cardiac in-
terstitial fibrosis was assessed by picrosirius red staining
(0.1 % w/v), excluding coronary vessels and perivascular
regions. Data were quantified by digital image analysis
(NIS-Elements, Nikon) with the observer blinded to sample
identity.
Immunohistochemistry for CD45 and F4/80 was per-
formed with rabbit polyclonal (Millipore), rat polyclonal
(BD Biosciences), and rat monoclonal (Abcam) antibodies
(1:1000), respectively, using diaminobenzidine as the
chromogen and nuclear counterstaining with haematoxylin.
Data were quantified by blinded digital image analysis
(NIS-Elements).
Cardiomyocyte apoptosis was determined by terminal
deoxynucleotidyl transferase-mediated dUTP nick end la-
belling (TUNEL) staining (Roche Diagnostics). TUNEL-
positive cardiomyocyte nuclei were counted, and data ex-
pressed as % total nuclei identified by 40,6-diamidino-2-
phenylindole staining in the same sections.
In vitro cardiomyocyte remodelling studies
To investigate direct effects of exendin-4 on cardiomyocyte
remodelling, a series of studies were conducted in rat ven-
tricular H9c2 cardiomyoblasts and mouse atrial HL-1 car-
diomyocytes, to assess actions on cell hypertrophy and
apoptosis, respectively. H9c2 cardiomyoblasts were main-
tained in DMEM containing 10 % FCS, 100 U/ml penicillin
and 100 lg/ml streptomycin. At passage, they were plated,
cultured to *50 % confluency and serum-starved for 24 h
prior to incubation with phenylephrine (1 lmol/L for 96 h)
to induce hypertrophy in the presence or absence of exendin-
4 (0.1 lmol/L) [33]. H9c2 cardiomyoblast cross-sectional
area was quantified by blinded digital image analysis (NIS-
Elements) as an index of cell hypertrophy. HL-1 cells were
maintained in Claycomb media containing 10 % FCS,
0.1 mmol/L norepinephrine, 2 mmol/L L-glutamate, 100 U/
ml penicillin and 100 lg/ml streptomycin. At passage, they
were plated and cultured to sub-confluency (70–80 %) prior
to incubation with doxorubicin (5 lmol/L for 24 h) to in-
duce apoptosis in the presence or absence of exendin-4
(0.1 lmol/L) [34]. Caspase 3/7 activity (Caspase-Glo,
Promega UK) was quantified as a measure of apoptosis and
data normalised to cell viability assessed by CellTiter-Blue
assay (Promega, UK).
Real-time reverse transcription-PCR
Total RNA was extracted from LV homogenate using TRI
reagent (Sigma-Aldrich), and cDNA synthesised by reverse
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transcription (Applied Biosystems). mRNA expression of
atrial natriuretic peptide (ANP), procollagen IaI, procol-
lagen IIIaI, connective tissue growth factor (CTGF), fi-
bronectin, TGF-b3, IL-10, IL-1b, IL-6 and GLP-1R was
analysed by real-time reverse transcription-PCR (RT-PCR)
using fluorescent SYBR Green (Prism 7300, Applied
Biosystems) and b-actin for normalisation by the com-
parative Ct method. Primer sequences are shown in Online
Resource 1.
Western blotting
LV protein was extracted by homogenisation with ice-cold
RIPA buffer, as previously described [31], and 20 lg
loaded onto a 10 % SDS-PAGE gel before blotting on a
polyvinylidene fluoride membrane (Immobilon-FL; Milli-
pore). Membranes were probed overnight at 4 C with
rabbit monoclonal antibodies (1:1000) against total glyco-
gen synthase kinase 3b (GSK3b; Cell Signaling Tech-
nology), phospho-GSK3b (Ser9; Cell Signaling
Technology) and discoidin domain receptor 2 (DDR2;
Abcam), and rabbit polyclonal antibodies (1:1000) against
total Akt, phospho-Akt (Ser473), Smad2/3 (both from Cell
Signaling Technology) and phospho-Smad2/3 (Ser423/
425; Santa Cruz Biotechnology), using rabbit polyclonal
HPRT2 antibody (Abcam; 1:1000) as a loading control.
This was followed by incubation with peroxidase-labelled
goat anti-rabbit secondary antibody (Cell Signaling Tech-
nology; 1:10,000) for 60 min at room temperature, before
the membrane was developed in a darkroom using ECL
reagent (Millipore), scanned and quantified by den-
sitometry (ImageJ).
Murine cardiac fibroblast isolation and culture
Murine cardiac fibroblasts were isolated from male
C57BL/6J mice based on a previously published method
[35]. Mice (5 per isolation) were euthanised with sodium
pentobarbitone (200 mg/kg i.p.) and heparin (100 IU/100 g
i.p.) and their hearts removed immediately into ice-cold
Krebs–Henseleit buffer (KHB). After rinsing twice in
KHB, ventricles were isolated, finely minced in KHB and
mixed vigorously with 4 ml LiberaseTM solution (Roche,
Sussex, UK) at 37 C for 8 min. The supernatant was then
removed and added to 10 ml ice-cold KHB to inhibit en-
zyme activity, whilst 3 ml LiberaseTM was added to the
undigested tissue and the process repeated a 3 further
times. The combined supernatant was filtered and cen-
trifuged at 200g for 5 min and the resultant pellet resus-
pended in DMEM supplemented with 10 % FBS,
20 mmol/L L-glutamine, 100 U/ml penicillin and 100 mg/
ml streptomycin, and transferred to a 1 % gelatin-coated
T75 flask with 10 ml DMEM at 37 C in a humidified
atmosphere of 5 % CO2. After 2 h, non-adherent cells were
removed and the remaining primary cardiac fibroblasts
cultured for approximately 7 days until 90 % confluent.
Cells were then washed with PBS, detached with 0.25 %
trypsin and centrifuged in DMEM at 200g for 5 min. The
cell pellet was suspended in fresh DMEM and fibroblasts
seeded at 1:2 for expansion before being used for ex-
periments at passage 2. Fibroblasts were treated with or
without TGF-b (5 ng/ml), to induce myofibroblast differ-
entiation, in the presence or absence of exendin-4 (10 n-
mol/L) for 24 h prior to assessment of gene expression.
Protein was prepared as described previously, and probed
for a-smooth muscle actin using a mouse monoclonal an-
tibody (Dako; 1:2000) and mouse monoclonal b-actin an-
tibody (Cell Signaling Technology; 1:50,000) as a loading
control. This was followed by incubation with Alexa
Fluor 594 goat anti-mouse (Molecular Probes; 1:10,000)
and horse anti-mouse (Cell Signaling Technology;
1:10,000) secondary antibodies, respectively, for 60 min at
room temperature, before membranes were developed in a
darkroom using ECL reagent (Millipore), scanned and
quantified by densitometry (ImageJ). The same a-smooth
muscle actin antibody was used at 1:200 to visualise actin
myofilament differentiation with DAPI nuclear counters-
taining imaged on a fluorescence microscope at 200x
magnification (Nikon Eclipse). RNA/cDNA was also pre-
pared as described previously, and CTGF mRNA expres-
sion assessed by real-time RT-PCR using fluorescent
SYBR Green and GAPDH for normalisation. Primer se-
quences are shown in Online Resource 1.
Murine bone marrow-derived macrophage isolation
and culture
Murine bone marrow-derived macrophages were iso-
lated from male C57BL/6J mice, as previously de-
scribed [36]. Mice were euthanised with sodium
pentobarbitone (200 mg/kg i.p.) and their femurs iso-
lated and rinsed in DMEM supplemented with 10 %
FBS and 100 U/ml penicillin and 100 mg/ml strepto-
mycin. Bone marrow cells were then flushed out with
fresh DMEM using a 23-gauge needle and centrifuged
at 500g for 10 min at 4 C. Media was aspirated and
cells were resuspended in ACK lysis buffer at room
temperature for 3 min to destroy any contaminating red
blood cells. The lysate was then quenched with excess
DMEM and centrifuged as before. Bone marrow cells
were then resuspended in DMEM supplemented with
L929 cell supernatant (1:6) containing macrophage
colony-stimulating factor to induce differentiation, and
seeded into a 150 mm tissue culture plate. At day 2,
media was replaced with fresh DMEM supplemented
with L929 supernatant to remove any non-adherent
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cells. At day 4, cells were washed and scraped into
DMEM prior to centrifugation at 500g for 10 min at
4 C, and seeded 1:3 into tissue culture plates con-
taining DMEM supplemented with L929 supernatant. At
day 8, cells were counted and split into 6-well plates,
each containing 1 million cells, prior to incubation for
a further 24 h in DMEM without L929 supernatant in
the presence or absence of exendin-4 (1 nmol/L). RNA/
cDNA and protein were then prepared for gene ex-
pression analysis, as described previously. mRNA ex-
pression of CD11b, IL-10, MMP-9, FGF-2, IL-1b and
CCL2 was analysed by real-time RT-PCR using
fluorescent SYBR Green and GAPDH for normalisation.
Primer sequences are shown in Online Resource 1.
Secreted cytokine expression was assessed in pooled
conditioned media from each experimental group using
a Proteome ProfilerTM antibody array (R&D Systems).
Immunocytochemistry for GLP-1R was performed in
both BMDM and cardiac fibroblasts using a rabbit
polyclonal antibody (Abcam: 1:200) with DAPI nuclear
counterstaining, whilst GLP-1R protein expression was
quantified in BMDM by Western blot using the same
primary antibody (1:1000) and a mouse monoclonal b-
actin antibody (Cell Signaling Technology: 1:50,000) as
the loading control.
Statistics
Data are expressed as mean ± SEM and were analysed by
either an unpaired t test, one-way ANOVA followed by a
Bonferroni or Dunnett’s multiple comparison test, or Ka-
plan–Meier survival analysis using a log-rank test.
P \ 0.05 was considered to be statistically significant.
Results
Metabolic data
Metabolic parameters are summarised in Table 1. Body
weight was not different between groups. Similarly,
chronic infusion with exendin-4 for 4 weeks had no effect
on plasma glucose, HbA1c, insulin, cholesterol or triglyc-
eride concentrations, whilst minimal differences in plasma
adipokine expression were observed (Online Resource 2).
Infarct size
Area at risk was similar between MI groups (control:
73.6 ± 2.0, exendin-4: 72.4 ± 2.3 % LV; n C 11) after
4 weeks. Infarct sizes were also comparable between MI
groups (control: 57.9 ± 4.2, exendin-4: 59.2 ± 4.3 % area
at risk; n C 11). However, survival rate at 4 weeks post-MI
tended to be higher after exendin-4 treatment (MI control:
67.6 %, n = 68; MI exendin-4: 80.3 %, n = 76;
P = 0.07). Only one death was observed in the sham
groups (n = 58).
Cardiac function
Echocardiography data are presented in Fig. 1a–d. LV di-
latation in response to MI, as measured by LVEDV, was
reduced by exendin-4. Similarly, exendin-4-treated mice
demonstrated improved systolic function post-MI, reflected
by higher ejection fraction and lower LVESV. Further-
more, diastolic dysfunction, indicated by a reduced mitral
valve E/A ratio in MI controls, was not evident after ex-
endin-4 treatment. Similar functional changes were ob-
served after assessment of LV dimension-derived
parameters (LVEDD, LVESD, fractional shortening) and
these data are presented in Online Resource 3. Heart rate
remained similar between groups.
Cardiac catheterisation data are summarised in Fig. 1e–
h. Post-MI decreases in systolic function, measured by
LVdP/dtmax, were attenuated by exendin-4. Similarly, ex-
endin-4-treated mice demonstrated better preserved LV
relaxation after MI, indexed by LVdP/dtmin and the iso-
volumetric relaxation time constant, s, and a tendency to-
wards improved diastolic function, reflected by reduced LV
end-diastolic pressure. Mean arterial blood pressure (con-
trol: 64.2 ± 0.9, exendin-4: 67.4 ± 1.2, MI control:
64 ± 2.7, 66.0 ± 1.6 mmHg; n = 9–15, P = NS) and
Table 1 Effect of exendin-4 on metabolic parameters
Sham control MI control Sham exendin-4 MI exendin-4
Body weight (g) n = 19 22.9 ± 0.4 23.7 ± 0.5 23.0 ± 0.3 23.2 ± 0.3
Plasma glucose (mmol/L) n = 7–12 13.6 ± 1.8 12.6 ± 0.7 13.1 ± 1.0 13.9 ± 0.9
Plasma HbA1c (%) n = 4–6 6.81 ± 0.23 6.90 ± 0.43 6.32 ± 0.32 6.08 ± 0.22
Plasma insulin (mmol/L) n = 10–12 0.56 ± 0.06 0.47 ± 0.04 0.53 ± 0.07 0.64 ± 0.11
Plasma cholesterol (mmol/L) n = 10–12 1.71 ± 0.07 1.88 ± 0.08 1.85 ± 0.09 1.84 ± 0.10
Plasma triglyceride (mmol/L) n = 10–11 1.32 ± 0.11 1.24 ± 0.14 0.90 ± 0.09 1.25 ± 0.11
Mean ± SEM. P = NS
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heart rate (control: 484 ± 24, exendin-4: 486 ± 16, MI
control: 478 ± 14, 472 ± 13 bpm; n = 9–15, P = NS)
remained similar between groups.
Cardiomyocyte remodelling
Chronic exendin-4 treatment reduced MI-induced myo-
cardial hypertrophy, as indicated by heart/body weight
ratio and cardiomyocyte area (Fig. 2a, b), although it had
no effect on mRNA expression of ANP (Fig. 2c), an
established marker of hypertrophy. Similarly, in vitro
phenylephrine-induced hypertrophy of H9c2 cardiomy-
oblasts was attenuated by exendin-4 (Fig. 2d). MI-induced
cardiomyocyte apoptosis, assessed in LV sections by
TUNEL staining, was also decreased by exendin-4
(Fig. 2e), although acute treatment had no significant effect
on in vitro doxorubicin-induced apoptosis in HL-1 car-
diomyocytes (Fig. 2f).
Extracellular matrix remodelling
Interstitial fibrosis was markedly decreased in exendin-4-
treated MI mice compared to MI controls (Fig. 3a–e).
Consistent with this, MI-induced increases in mRNA ex-
pression of several key ECM genes, procollagen IaI, pro-
collagen IIIaI, CTGF, fibronectin and TGF-b3, were
reduced by exendin-4 (Fig. 3f–j). In addition, protein ex-
pression of the fibroblast marker, DDR2, was increased in
MI exendin-4-treated mice compared to MI controls
(Fig. 3k) [37, 38].
Myocardial inflammation
Myocardial infiltration of CD45-positive leukocytes and
F4/80-positive macrophages after MI was completely pre-
vented by exendin-4 (Fig. 4a–k). Consistent with this, MI-
induced alterations in mRNA expression of the inflamma-
tory cytokines, IL-10, IL-1b and IL-6, were normalised by
exendin-4 (Online Resource 4).
GLP-1R receptor expression
GLP-1R mRNA expression was increased in MI controls
and attenuated by exendin-4 (Online Resource 5).
Investigation of potential cardioprotective signalling
mechanisms
Several candidate pathways which may mediate the pro-
tective effects of exendin-4 on post-MI remodelling were
investigated. Phosphorylation of the pro-survival kinase
Akt was clearly elevated by exendin-4 after MI, in asso-
ciation with an apparent increase in total protein expression
(Fig. 5a–c). Furthermore, both total and phosphorylated
GSK-3b, a known substrate of Akt, which has been pro-
posed as a convergence point for several cardioprotective
pathways and specifically suppresses cardiac fibroblast-
driven remodelling [39, 40], was markedly increased by
exendin-4 (Fig. 5d–f), indicating deactivation of GSK-3b
signalling. In addition, the expression and activity of two
key Smad proteins, which are important regulators of TGF-
Fig. 1 Effect of exendin-4 on cardiac function post-MI. a LV end-
diastolic volume (LVEDV), b LV end-systolic volume (LVESV),
c LV ejection fraction, d mitral valve (MV) E/A ratio, assessed by
echocardiography (n = 10–16). e LV dP/dtmax; f LV dP/dtmin; g s;
h LV end-diastolic pressure (LVEDP), assessed by cardiac
catheterisation (n = 9–15). White columns sham, black columns MI,
mean ± SEM. *P \ 0.05, **P \ 0.01, ***P \ 0.001, versus corre-
sponding sham; P \ 0.05, P \ 0.01, MI exendin-4 versus MI
control
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Fig. 2 Effect of exendin-4 on cardiomyocyte remodelling after MI.
a Heart weight/body weight (HW/BW; n = 24–29), b cardiomyocyte
cross-sectional area (n = 6), c ANP mRNA expression (n = 6–8),
d phenylephrine-induced H9c2 cardiomyoblast hypertrophy
(n = 7–8), e TUNEL staining (n = 6), f doxorubicin-induced HL-1
cardiomyocyte apoptosis (n = 6). White columns sham (a–c, e) or
untreated cells (d, f); black columns MI (a–c, e) or phenyle-
phrine/doxorubicin-treated cells (d, f); mean ± SEM. **P \ 0.01,
***P \ 0.001, versus corresponding sham/untreated control;
P \ 0.05, P \ 0.001, MI exendin-4 versus MI control or
phenylephrine exendin-4 versus phenylephrine control
Fig. 3 Effect of exendin-4 on ECM remodelling after MI. a–
d Representative LV sections stained with picrosirius red to assess
interstitial fibrosis, e quantification data (n = 6). f–j mRNA expres-
sion of ECM genes by real-time RT-PCR (n = 5–12), k DDR2
protein expression by Western blot (n = 6). White columns
sham; black columns MI; mean ± SEM. *P \ 0.05, **P \ 0.01,
***P \ 0.001, versus corresponding sham; P \ 0.05,
P \ 0.001, MI exendin-4 versus MI control
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b signalling and ECM turnover with documented cardio-
protective actions [41, 42], were specifically modulated by
exendin-4 post-MI. MI-induced decreases in both total and
phosphorylated Smad2 and Smad3 were prevented by ex-
endin-4, although the drug itself also reduced total protein
expression in shams (Fig. 6a–f).
Cell studies
To investigate cell-specific effects of exendin-4 relevant to
post-MI remodelling, a series of mechanistic studies were
conducted in murine cardiac fibroblasts and BMDM. Ex-
endin-4 had no effect on basal and TGF-b-stimulated a-
SMA and CTGF expression in cardiac fibroblasts (Fig. 7a–
c). In addition, actin myofilament density, visualised by a-
SMA staining, was similar between fibroblasts treated
with/without TGF-b in the presence/absence of exendin-4
(Fig. 7d–g), confirming that exendin-4 does not appear to
exert direct effects on these cells. Further studies confirmed
previous reports that cardiac fibroblasts do not express the
GLP-1R [8], whilst significant GLP-1R expression was
detected in BMDM which appeared to be increased by
exendin-4 (Online Resource 6). Notably, treatment of
BMDM with exendin-4 for 24 h resulted in modulation of
several macrophage response genes relevant to tissue re-
pair/remodelling. Cellular mRNA expression of CD11b,
MMP-9 and FGF-2 was reduced with that of IL-10, IL-1-b,
and CCL2 increased (Fig. 8a–f), whilst levels of key se-
creted proteins (CXCL10, CXCL1, CCL2, TIMP-1) were
decreased by exendin-4 (Fig. 8g, h).
Discussion
Here, it is reported for the first time that chronic GLP-1R
activation post-MI protects against adverse ventricular re-
modelling via specific actions on individual remodelling
components which appear to involve preferential targeting
of inflammation and the ECM. This study clearly demon-
strates that exendin-4 protects against cardiac contractile
Fig. 4 Effect of exendin-4 on myocardial inflammation after MI.
Representative LV sections stained for a–e CD45, with positive
spleen control, and g–j F4/80, to assess leukocyte and macrophage
infiltration, respectively. f, k Quantification data (n = 5–6). White
columns sham; black columns MI; mean ± SEM. ***P \ 0.001,
versus corresponding sham; P \ 0.01, P \ 0.001, MI exendin-4
versus MI control
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dysfunction after experimental MI, which is associated
with reduced cardiomyocyte hypertrophy/apoptosis, and
marked attenuation of myocardial inflammation and ECM
remodelling. Importantly, these beneficial effects on post-
MI remodelling occurred independently of the established
glycaemic and acute cardioprotective actions of GLP-1 and
were associated with modulation of both Akt/GSK-3b and
Smad2/3 signalling and improved survival. Furthermore,
complementary cell studies found that exendin-4
modulated macrophage response gene expression and
protein secretion, but had no effect on differentiation of
cardiac fibroblasts, which do not express the GLP-1R,
suggesting that the observed actions on ECM remodelling
may occur secondary to modulation of myocardial
inflammation, although it is likely that cardiomyocyte
signalling pathways are also involved.
The rationale for this investigation was based on several
studies indicating that GLP-1R activation confers protec-
tion against acute ischaemic damage [8, 19, 20] and two
subsequent reports that GLP-1 analogues administered
2 days and 2 weeks post-MI improve survival and cardiac
structure/function [23, 43]. Here, we chose to employ an
alternate treatment regimen of continuous exendin-4 infu-
sion starting immediately after MI or sham surgery to
specifically assess effects on distinct aspects of post-MI
remodelling independently of GLP-1R-mediated altera-
tions in acute infarct remodelling. Indeed, area at risk and
infarct size measurements were comparable between
Fig. 5 Effect of exendin-4 on Akt and GSK3b expression after MI.
Representative Western blots for total and phosphorylated a Akt, and
d GSK-3b; blots were stripped and reprobed and normalised to
HPRT2, which is displayed within each panel for comparison. b, c, e,
f Quantification data (n = 6). White columns sham; black columns
MI; mean ± SEM. *P \ 0.05, **P \ 0.01, versus corresponding
sham; P \ 0.01, P \ 0.001, MI exendin-4 versus MI control;
P \ 0.01, P \ 0.001, sham exendin-4 versus sham control
Fig. 6 Effect of exendin-4 on Smad2/3 expression after MI. Repre-
sentative Western blots for total and phosphorylated a Smad2, and
d Smad3; blots were stripped and reprobed and normalised to HPRT2,
which is displayed within each panel for comparison. b–c, e–
f Quantification data (n = 6). White columns sham; black columns
MI; mean ± SEM. **P \ 0.01, versus corresponding sham;
P \ 0.05, P \ 0.001, MI exendin-4 versus MI control;
P \ 0.01, P \ 0.001, sham exendin-4 versus sham control
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groups indicating that the observed effects were likely to be
due to direct actions on post-MI ventricular remodelling.
Importantly, the concentration of exendin-4 employed in
our study was comparable to those commonly used in
previous rodent studies relating to the anti-diabetic and
cardioprotective actions of GLP-1 [12, 15, 16, 32]. Fur-
thermore, our studies were performed in wild-type mice, in
which body weight and circulating glucose, insulin and
lipids were unaltered by exendin-4, together with minimal
changes in adipokine expression, suggesting that the re-
ported cardiac effects are likely to be due to direct actions
of exendin-4, although it is impossible to completely ex-
clude peripheral effects.
Several previous studies have indicated that GLP-1
modulates basal cardiac function and protects against
contractile dysfunction associated with both experimental
and clinical CHF [10, 13, 14, 16, 18, 21, 22]. Indeed in our
study, the development of MI-induced systolic dysfunction
(increased LVESV, decreased ejection fraction and
LVdPdtmax) was attenuated by exendin-4. Chronic treat-
ment with exendin-4 also improved LV relaxation after MI
(increased LVdP/dtmin, reduced s) and protected against
Fig. 7 Effect of exendin-4 on isolated murine cardiac fibroblasts.
a Representative Western blot for a-SMA in cardiac fibroblasts
treated with/without TGF-b (5 ng/ml) in the presence/absence of
exendin-4 (Ex-4; 10 nmol/L) for 24 h; blots were stripped and
reprobed and normalised to b-actin. b a-SMA protein quantification
data (n = 8). c CTGF mRNA expression in cardiac fibroblasts by
real-time RT-PCR (n = 6). d–g Representative images of cardiac
fibroblasts stained for a-SMA to visualise myofibroblast differ-
entiation with DAPI nuclear counterstaining. Data are mean ± SEM.
*P \ 0.05, **P \ 0.01; ***P \ 0.001, versus corresponding control
Fig. 8 Effect of exendin-4 on inflammatory gene expression in
isolated BMDM. a–f Cellular mRNA expression by real-time RT-
PCR (n = 6–8), and g, h conditioned media cytokine protein array
blots, of macrophage response genes from BMDM treated with/
without exendin-4 (Ex-4; 1 nmol/L) for 24 h. Data are mean ± SEM.
*P \ 0.05, **P \ 0.01; ***P \ 0.001, versus corresponding control
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diastolic dysfunction (preserved mitral valve E/A ratio,
reduced LV end-diastolic pressure). Furthermore, LV di-
latation (measured by LVEDD and LVEDV) observed in
MI control mice was reduced by exendin-4.
It seems reasonable to conclude that the marked atten-
uation of cardiac contractile dysfunction by exendin-4
post-MI occurred secondary to beneficial actions on both
the cardiomyocyte and ECM, which are established as key
remodelling components in this setting [3]. Indeed, ex-
endin-4 caused modest reductions in morphometric
heart/body weight and cardiomyocyte cross-sectional area
after MI, together with reduced in vivo cardiomyocyte
apoptosis. Acute exendin-4 treatment also inhibited in vitro
phenylephrine-induced H9c2 cardiomyoblast hypertrophy
but failed to reduce doxorubicin-induced apoptosis of HL-1
cardiomyocytes, assessed by caspase 3/7 activation. How-
ever, it is important to highlight that our conducted
assessment of cardiomyocyte apoptosis was minimal as
only a single output was measured in both ventricular tis-
sue and cultured cells which represents a significant
limitation. Nonetheless, other studies have consistently
shown GLP-1 to protect cardiomyocytes from apoptosis
both in vivo and in vitro [15, 30], although reported effects
on cardiomyocyte hypertrophy have been varied. Whilst
some have reported the DPP-4 inhibitor, sitagliptin, and
exendin-4 to have no effect on cardiomyocyte hypertrophy
in experimental MI and type 1 diabetes, respectively, oth-
ers have shown that GLP-1R activation with liraglutide
reduces cardiomyocyte hypertrophy after both MI and
high-fat feeding [15, 44–46]. Therefore, it is maybe not
surprising that exendin-4 exerted only modest effects on
post-MI cardiomyocyte remodelling, which may have oc-
curred directly or secondary to more pronounced effects on
the ECM.
Indeed, contractile function is particularly sensitive to
ECM remodelling, and exendin-4 markedly reduced MI-
induced increases in interstitial fibrosis and ECM gene
expression, which is likely to significantly contribute to the
associated improvement of LV relaxation (LVdP/dtmin, s)
and tendency towards increased diastolic function (mitral
valve E/A ratio, LV end-diastolic pressure). Interestingly,
this was associated with marked increases in myocardial
expression of DDR2 in MI exendin-4 animals, which is an
established fibroblast marker also known to modulate col-
lagen biosynthesis [37, 38]. As far as we are aware, these
data provide the first direct evidence that GLP-1R activa-
tion modulates ECM remodelling, a finding which may
have important implications for the use of GLP-1-based
therapies in diabetic patients, who are frequently charac-
terised by a disproportionate accumulation of collagen
within the heart [47]. Interestingly, our complementary
studies in cardiac fibroblasts found that exendin-4 had no
effect on TGF-b-induced cell differentiation, which is
maybe not surprising as cardiac fibroblasts are known not
to express the GLP-1R [8], and suggests that the observed
effects on ECM remodelling may be mediated via another
cell type. Indeed, we found that myocardial GLP-1R ex-
pression was increased after MI (which may represent an
adaptive response) and was normalised by exendin-4,
although it is also possible that the mechanism may involve
established GLP-1R-independent pathways [8, 48].
The most likely remodelling process by which exendin-
4 may mediate indirect effects on the cardiac fibroblast
would appear to be inflammation, which is becoming in-
creasingly recognised as an important mediator of post-MI
remodelling capable of exerting specific regulatory actions
on several remodelling components, but which preferen-
tially targets the ECM [43, 49]. Indeed, in this study, ex-
perimental MI was associated with marked myocardial
infiltration of CD45? leukocytes and F4/80? macrophages
and altered expression of inflammatory cytokines, IL-10
(known regulator of tissue remodelling), IL-1b and IL-6
(both critical for fibroblast differentiation) [50, 51]. Im-
portantly, exendin-4 completely prevented these changes
suggesting that the observed benefits on post-MI remod-
elling may have occurred, at least partly, secondary to
modulation of inflammation, which is consistent with
previous reports of anti-inflammatory actions in other or-
gans, such as the pancreas [29]. Furthermore, comple-
mentary experiments in BMDM, which expressed the
GLP-1R, found that exendin-4 differentially modulated
basal levels of both resident and secreted macrophage re-
sponse genes, which are known to contribute to tissue re-
modelling and repair [52, 53]. Exendin-4 decreased
macrophage expression of both CD11b, which plays a key
role in monocyte adhesion, and MMP-9 and FGF-2 which
are important drivers of ECM remodelling, whilst tissue-
protective IL-10 and pro-inflammatory IL-1b and CCL2
were upregulated. Furthermore, exendin-4 reduced levels
of secreted CXCL10, CXCL1, CCL2 and TIMP-1, all of
which are key modulators of macrophage function [49].
Taken together, these data clearly suggest that the observed
effects of exendin-4 on ECM remodelling are mediated, at
least partly via indirect macrophage-driven actions on the
cardiac fibroblast. However, the underlying mechanisms
are likely to be complex and require detailed further
investigation.
As previous studies focusing on the acute cardiopro-
tective actions of GLP-1 have consistently demonstrated
modulation of both Akt and GSK-3b [15, 16, 20], we chose
to investigate effects of exendin-4 on this pathway in the
setting of post-MI remodelling. Indeed, in our study, Akt
and also GSK-3b, which has been reported to specifically
suppress cardiac fibroblast-mediated remodelling [39],
were upregulated by exendin-4 after MI, at both total and
phosphorylated protein level, suggesting that modulation of
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cardiomyocyte Akt/GSK-3b signalling plays a key role in
mediating the chronic cardioprotective actions of GLP-1R
activation and may thereby indirectly influence ECM re-
modelling. Notably, chronic cardiomyocyte-specific Akt
activation has recently been shown to promote both
pathological hypertrophy and fibrosis [54], supporting the
suggestion that exendin-4 induced modulation of car-
diomyocyte Akt/GSK-3b signalling may contribute to the
observed ECM effects. In addition to its effects on Akt/
GSK-3b signalling, exendin-4 prevented MI-induced de-
creases in phosphorylated Smad2 and Smad3, indicating
that it may promote activity of these two key Smad proteins
in the viable myocardium post-MI. Although Smad2 and
Smad3 signalling are closely linked [40], their precise role
in cardiac remodelling is unknown. For example, some
studies indicate that they may exert divergent cardiac ac-
tions, with Smad3 being pro-fibrotic and Smad2 protective
against cardiomyocyte remodelling, whereas others suggest
that cardiac fibrosis is promoted by Smad2 and inhibited by
Smad3 [39, 41, 55, 56]. Interestingly, other groups have
also questioned the dependence of cardiac Smad signalling
on TGF-b [57, 58]. Therefore, although it appears that
exendin-4 exerts its benefits on post-MI remodelling, at
least partly via activation of Smad2/3, the precise nature of
these actions remains unclear.
Although our data clearly suggest that exendin-4 exerts
distinct protective actions on post-MI remodelling via ap-
parently preferential modulation of myocardial inflamma-
tion and the ECM, it is important to consider several
limitations. A major issue with such studies is the inherent
risk of selection bias as only surviving animals are studied,
so it is possible that infarcts may have been larger in MI
controls thereby explaining their tendency towards in-
creased mortality. However, MI animals generally died
within 7 days due to cardiac rupture, as opposed to acute
heart failure, which is more likely to reflect impaired
wound healing, and further to our 4-week data, may indeed
be expected to be improved by exendin-4. In addition, as
exendin-4 was infused immediately post-MI, it seems un-
likely that this treatment would affect area at risk and ex-
tent of infarction. In this regard, it should be noted that
sample numbers were not consistently lower in MI control
versus exendin-4 treated animals and that any disparities
were due to practical or technical issues. There are also
potential limitations with our experimental model. Firstly,
while there is a general argument that both sexes should be
included in disease investigation, only female mice were
assessed here due to animal welfare considerations. Indeed,
we have previously employed female mice for post-MI
remodelling studies as have several other leading groups
[31, 59, 60]. Secondly, we chose to induce permanent
coronary artery ligation and so the influence of reperfusion
could not be studied. Thirdly, we used a supra-clinical dose
of exendin-4 to identify specific remodelling actions and
effects of lower therapeutic levels were not assessed. Fur-
thermore, as our initial aim was to precisely define the
actions of exendin-4 on post-MI remodelling by focussing
on individual components, no primary end point was se-
lected. It is also important to recognise that the use of cell
lines to interrogate in vitro effects of exendin-4 on car-
diomyocyte hypertrophy may have limited relevance to the
in vivo setting, although they may still provide useful
complementary data. Nonetheless, our findings indicate
that exendin-4 protects against post-MI remodelling and
promotes preferential modulation of the ECM. However,
although our in vivo data show clear differences in myo-
cardial inflammation and our in vitro data suggest that
macrophage signalling may be a potential target for ex-
endin-4 in this setting, we cannot conclude that the ob-
served ECM effects are specifically mediated via
macrophage/fibroblast interaction without more sophisti-
cated in vitro and in vivo studies. Similarly, the effects of
exendin-4 on cardiomyocyte signalling pathways need to
be further interrogated to establish their precise influence
on post-MI remodelling.
Despite these limitations, our data strongly suggest that
exendin-4 exerts distinct protective actions on post-MI
remodelling, independent of its established metabolic and
glycaemic effects, which appear to be mediated via pref-
erential modulation of myocardial inflammation and the
ECM. Whilst noting that cardiomyocyte signalling path-
ways are also altered by exendin-4 and so are likely to
directly or indirectly influence post-MI remodelling, our
findings clearly indicate that exendin-4 exerts distinct ac-
tions on specific aspects of post-MI remodelling, and to-
gether with previous studies reporting both acute and
chronic cardioprotective effects, highlight the potential of
GLP-1-based therapeutic strategies. In this regard, it should
be noted that the first large-scale GLP-1 cardiovascular
trials recently reported that the DPP-4 inhibitors,
saxagliptin and alogliptin, did not confer cardiovascular
benefit in type 2 diabetes [61, 62], although there are
currently no data from long-term randomised clinical trials
with GLP-1R agonists, with several ongoing [7]. Although
circulating GLP-1 levels in patients treated with DPP-4
inhibitors are much lower than those achieved using GLP-
1R agonists, the seemingly disappointing results of these
recent trials would appear to support our suggestion that a
more selective approach targeted towards specific post-MI
remodelling components may be required to realise the
clear potential of GLP-1-based strategies in this setting.
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